Department of Pharmacy - Drug Sciences, University of Bari Aldo Moro, Bari, Italy.
U.O.C. Bioterapie, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Anticancer Agents Med Chem. 2024;24(8):637-647. doi: 10.2174/0118715206282904240122063914.
Ovarian cancer (OC) is one of the most prevalent malignancies in female reproductive organs, and its 5-year survival is below 45%. Despite the advances in surgical and chemotherapeutic options, OC treatment is still a challenge, and new anticancer agents are urgently needed. Drug repositioning has gained significant attention in drug discovery, representing a smart way to identify new clinical applications for drugs whose human safety and pharmacokinetics have already been established, with great time and cost savings in pharmaceutical development endeavors. This review offers an update on the most promising drugs repurposable for OC treatment and/or prevention.
卵巢癌（OC）是女性生殖器官中最常见的恶性肿瘤之一，其 5 年生存率低于 45%。尽管手术和化疗选择有所进步，但 OC 的治疗仍然是一个挑战，迫切需要新的抗癌药物。药物再定位在药物发现中引起了广泛关注，它代表了一种识别已确立人类安全性和药代动力学的药物新临床应用的明智方法，在药物开发方面节省了大量时间和成本。本文综述了最有前途的可重新用于 OC 治疗和/或预防的药物。
